Bosh sahifaAMLX • NASDAQ
add
Amylyx Pharmaceuticals Inc
3,49 $
Seans yopilganidan keyin:(0,00%)0,00
3,49 $
Yopilgan:27-yan, 16:02:00 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
3,60 $
Kunlik diapazon
3,45 $ - 3,66 $
Yillik diapazon
1,58 $ - 19,95 $
Bozor kapitalizatsiyasi
299,05 mln USD
Oʻrtacha hajm
889,69 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 416,00 ming | -99,59% |
Joriy xarajat | 17,83 mln | -63,41% |
Sof foyda | -72,70 mln | -447,98% |
Sof foyda marjasi | -17,48 ming | -85 981,67% |
Har bir ulushga tushum | -1,07 | -456,67% |
EBITDA | -75,44 mln | -496,59% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 234,40 mln | -33,98% |
Jami aktivlari | 250,71 mln | -46,27% |
Jami passivlari | 54,51 mln | 13,13% |
Umumiy kapital | 196,20 mln | — |
Tarqatilgan aksiyalar | 68,55 mln | — |
Narxi/balansdagi bahosi | 1,26 | — |
Aktivlardan daromad | -64,90% | — |
Kapitaldan daromad | -81,67% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -72,70 mln | -447,98% |
Operatsiyalardan naqd pul | -41,57 mln | -704,22% |
Sarmoyadan naqd pul | 38,82 mln | 135,91% |
Moliyadan naqd pul | 80,00 ming | -91,00% |
Naqd pulning sof oʻzgarishi | -2,44 mln | 97,83% |
Boʻsh pul | -86,18 mln | -1 426,30% |
Haqida
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
Tashkil etilgan
2013
Sayt
Xodimlar soni
384
